{"id":"https://openalex.org/W2111361801","doi":"https://doi.org/10.1185/03007990903434914","title":"A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer\u2019s disease: a post hoc analysis","display_name":"A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer\u2019s disease: a post hoc analysis","alternate_titles":[],"publication_year":2009,"publication_date":"2009-11-24","ids":{"openalex":"https://openalex.org/W2111361801","doi":"https://doi.org/10.1185/03007990903434914","mag":"2111361801","pmid":"https://pubmed.ncbi.nlm.nih.gov/19929593"},"language":"en","primary_location":{"id":"doi:10.1185/03007990903434914","doi":"https://doi.org/10.1185/03007990903434914","is_oa":false,"landing_page_url":"https://doi.org/10.1185/03007990903434914","pdf_url":null,"source":{"id":"https://openalex.org/S206643269","display_name":"Current Medical Research and Opinion","issn_l":"0300-7995","issn":["0300-7995","1473-4877"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Medical Research and Opinion","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2111361801"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5071364728","display_name":"Martin Rhys Farlow","orcid":"https://orcid.org/0000-0001-7897-5471","observed_orcids":["https://orcid.org/0000-0001-7897-5471"]},"institutions":[{"id":"https://openalex.org/I4394709130","display_name":"Indiana University School of Medicine","ror":"https://ror.org/02ets8c94","country_code":"US","type":"education","lineage":["https://openalex.org/I4394709130","https://openalex.org/I592451"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Martin R. Farlow","raw_affiliation_strings":["Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I4394709130"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111762880","display_name":"Gus Alva","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210148672","display_name":"ATP Clinical Research (United States)","ror":"https://ror.org/04pmrdd93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210148672"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gus Alva","raw_affiliation_strings":["ATP Clinical Research, Costa Mesa, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ATP Clinical Research, Costa Mesa, CA, USA","institution_ids":["https://openalex.org/I4210148672"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101721800","display_name":"Xiangyi Meng","orcid":"https://orcid.org/0000-0002-2034-4551","observed_orcids":["https://orcid.org/0000-0002-2034-4551"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Xiangyi Meng","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5052290960","display_name":"Jason T. Olin","orcid":"https://orcid.org/0000-0002-7293-6428","observed_orcids":["https://orcid.org/0000-0002-7293-6428"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jason T. Olin","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5071364728"],"corresponding_institution_ids":["https://openalex.org/I4394709130"],"apc_list":null,"apc_paid":null,"fwci":4.7558,"has_fulltext":false,"cited_by_count":65,"citation_normalized_percentile":{"value":0.94377754,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"26","issue":"2","first_page":"263","last_page":"269"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.42899999022483826,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.42899999022483826,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.3813000023365021,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.16930000483989716,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rivastigmine","display_name":"rivastigmine","score":0.8240000009536743},{"id":"https://openalex.org/keywords/transdermal-patch","display_name":"transdermal patch","score":0.9070000052452087},{"id":"https://openalex.org/keywords/memantine","display_name":"memantine","score":0.9559999704360962},{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.9819999933242798},{"id":"https://openalex.org/keywords/mild-to-moderate-dementia","display_name":"mild to moderate dementia","score":0.7990000247955322},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.531000018119812},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.7360000014305115},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.9779999852180481},{"id":"https://openalex.org/keywords/cognitive-function","display_name":"cognitive function","score":0.7459999918937683},{"id":"https://openalex.org/keywords/activities-of-daily-living","display_name":"activities of daily living","score":0.9860000014305115},{"id":"https://openalex.org/keywords/global-functioning","display_name":"global functioning","score":0.6959999799728394},{"id":"https://openalex.org/keywords/cholinesterase-inhibitors","display_name":"cholinesterase inhibitors","score":0.8159999847412109},{"id":"https://openalex.org/keywords/nmda-receptor-antagonist","display_name":"NMDA receptor antagonists","score":0.7490000128746033},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.5770000219345093},{"id":"https://openalex.org/keywords/gastrointestinal-side-effects","display_name":"gastrointestinal adverse effects","score":0.5950000286102295},{"id":"https://openalex.org/keywords/post-hoc-analysis","display_name":"post hoc analysis","score":0.609000027179718},{"id":"https://openalex.org/keywords/dose-titration","display_name":"dose titration","score":0.574999988079071}],"concepts":[{"id":"https://openalex.org/C2779484449","wikidata":"https://www.wikidata.org/wiki/Q412189","display_name":"Memantine","level":4,"score":0.9140012264251709},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8684408664703369},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8623980283737183},{"id":"https://openalex.org/C2776332859","wikidata":"https://www.wikidata.org/wiki/Q411887","display_name":"Rivastigmine","level":5,"score":0.8580288887023926},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.7770079970359802},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6324448585510254},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.5994558334350586},{"id":"https://openalex.org/C2780904820","wikidata":"https://www.wikidata.org/wiki/Q415081","display_name":"Donepezil","level":4,"score":0.5691173076629639},{"id":"https://openalex.org/C2775842315","wikidata":"https://www.wikidata.org/wiki/Q1145270","display_name":"Transdermal patch","level":3,"score":0.5114558935165405},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.482862263917923},{"id":"https://openalex.org/C67761136","wikidata":"https://www.wikidata.org/wiki/Q2105849","display_name":"Post-hoc analysis","level":2,"score":0.44251909852027893},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.43171966075897217},{"id":"https://openalex.org/C205679159","wikidata":"https://www.wikidata.org/wiki/Q3375179","display_name":"Transdermal","level":2,"score":0.3647819757461548},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.33097589015960693},{"id":"https://openalex.org/C2779483572","wikidata":"https://www.wikidata.org/wiki/Q83030","display_name":"Dementia","level":3,"score":0.30148836970329285},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.12007710337638855}],"mesh":[{"descriptor_ui":"D000068836","descriptor_name":"Rivastigmine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077265","descriptor_name":"Donepezil","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000279","descriptor_name":"Administration, Cutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000465","descriptor_name":"Algorithms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D000978","descriptor_name":"Antiparkinson Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000978","descriptor_name":"Antiparkinson Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D002800","descriptor_name":"Cholinesterase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002800","descriptor_name":"Cholinesterase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007189","descriptor_name":"Indans","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008559","descriptor_name":"Memantine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D008559","descriptor_name":"Memantine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018696","descriptor_name":"Neuroprotective Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018696","descriptor_name":"Neuroprotective Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D048448","descriptor_name":"Phenylcarbamates","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D048448","descriptor_name":"Phenylcarbamates","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1185/03007990903434914","doi":"https://doi.org/10.1185/03007990903434914","is_oa":false,"landing_page_url":"https://doi.org/10.1185/03007990903434914","pdf_url":null,"source":{"id":"https://openalex.org/S206643269","display_name":"Current Medical Research and Opinion","issn_l":"0300-7995","issn":["0300-7995","1473-4877"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Medical Research and Opinion","raw_type":"journal-article"},{"id":"pmid:19929593","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19929593","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current medical research and opinion","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":7,"referenced_works":["https://openalex.org/W1971792062","https://openalex.org/W2004305668","https://openalex.org/W2026047746","https://openalex.org/W2082987115","https://openalex.org/W2141339944","https://openalex.org/W2143879671","https://openalex.org/W2182271449"],"related_works":["https://openalex.org/W1977427195","https://openalex.org/W2267702763","https://openalex.org/W2005789157","https://openalex.org/W2052011640","https://openalex.org/W1603277425","https://openalex.org/W2063443588","https://openalex.org/W2114977515","https://openalex.org/W1975507089","https://openalex.org/W2132095353","https://openalex.org/W2773716043"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"investigate":[2],"the":[3,8,103,139,148,158,182,250],"tolerability":[4],"and":[5,87,89,94,115,121,129,134,143,151,154,167,192,197,227,273],"efficacy":[6,90],"of":[7,28,96,162,202,249],"rivastigmine":[9,42,104,119,251],"transdermal":[10,105,252],"patch":[11,253],"in":[12,176,207,216,225,237,242,254,268],"patients":[13,117,132,177,217,255],"with":[14,107,120,133,245,263,271],"mild-to-moderate":[15],"Alzheimer's":[16],"disease":[17],"receiving":[18,37,178],"concomitant":[19,110,179],"memantine.":[20,111,246],"RESEARCH":[21],"DESIGN":[22],"AND":[23],"METHODS:":[24],"Post":[25],"hoc":[26],"analysis":[27],"a":[29,50,66],"25-week,":[30],"randomized,":[31],"prospective,":[32],"open-label,":[33],"parallel-group":[34],"study.":[35,159],"Patients":[36],"donepezil":[38],"were":[39,100,172,184,230],"switched":[40],"to":[41,61,212,260,277],"patches":[43],"(4.6":[44],"mg/24":[45,63],"h)":[46],"immediately":[47],"or":[48,108,280],"following":[49],"7-day":[51],"withdrawal":[52],"for":[53,65,102,195],"4":[54],"weeks":[55],"(core":[56],"phase),":[57],"before":[58],"titrating":[59],"up":[60],"9.5":[62],"h":[64],"further":[67],"20-week":[68],"extension":[69,149],"phase.":[70],"Prior":[71],"memantine":[72,220,258],"therapy":[73],"was":[74,205,214],"continued":[75],"throughout.":[76],"MAIN":[77],"OUTCOME":[78],"MEASURES:":[79],"Tolerability":[80],"(adverse":[81],"events":[82],"[AEs],":[83],"serious":[84],"AEs":[85,163,196,204,213,269],"[SAEs]":[86],"discontinuations)":[88],"(cognition,":[91],"global":[92,228,281],"functioning":[93,282],"activities":[95],"daily":[97],"living":[98],"[ADLs])":[99],"assessed":[101],"patch,":[106],"without":[109,122,135],"RESULTS:":[112],"Overall,":[113],"135":[114],"126":[116],"received":[118,219],"memantine,":[123,136,180],"respectively.":[124],"Of":[125],"these,":[126],"122":[127],"(90.4%)":[128],"118":[130],"(93.7%)":[131],"respectively,":[137,146],"completed":[138,157],"core":[140],"phase;":[141],"120":[142],"114":[144],"patients,":[145],"entered":[147],"phase,":[150],"90":[152],"(75.0%)":[153],"86":[155],"(75.4%)":[156],"The":[160,200],"incidences":[161],"(73.3":[164],"vs.":[165,170,222],"67.5%)":[166],"SAEs":[168],"(10.4":[169],"7.1%)":[171],"both":[173,208,238],"slightly":[174],"larger":[175],"but":[181],"differences":[183],"not":[185,275],"statistically":[186],"significant":[187],"(95%":[188],"CIs:":[189],"-5.2,":[190],"16.9":[191],"-3.6,":[193],"10.1":[194],"SEAs,":[198],"respectively).":[199],"incidence":[201],"gastrointestinal":[203],"low":[206],"groups.":[209,233],"Discontinuation":[210],"due":[211],"higher":[215],"who":[218],"(17.0":[221],"11.9%).":[223],"Changes":[224],"cognitive":[226],"function":[229],"similar":[231],"between":[232],"ADL":[234],"scores":[235],"worsened":[236],"groups;":[239],"significantly":[240],"more":[241],"those":[243],"treated":[244],"CONCLUSION:":[247],"Use":[248],"on":[256],"established":[257],"appears":[259],"be":[261],"well-tolerated,":[262],"only":[264],"modest,":[265],"non-significant":[266],"increases":[267],"compared":[270],"monotherapy,":[272],"did":[274],"seem":[276],"affect":[278],"cognition":[279],"adversely.":[283]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2111361801","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":9}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
